Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
Condition: EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma Intervention: Drug: Icotinib combined dihydroaremisinin Sponsors: Beijing Cancer Hospital; Betta Pharmaceuticals Co.,Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Hospitals | Lung Cancer | Non-Small Cell Lung Cancer | Research